Clinical trial · Interventional
Intravenous Iron: Measuring Response in Anemic Surgical Patients
An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
20 Patients will be recruited with confirmed colorectal adenocarcinoma and anemia who are planned to undergo surgery. All patients will be treated with a single dose of 1g intravenous ferric carboxymaltose (FERINJECT). It is hypothesized that intravenous iron supplementation is efficacious at raising haemoglobin levels and reduced blood transfusion requirements.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Colorectal Neoplasm | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravenous ferric carboxymaltose | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intravenous Ferric Carboxymaltose
- description
- All recruited patients will be allocated to this treatment. 1 gram of Ferric carboxymaltose (FERINJECT) to be given at recruitment
- interventionNames
- Drug: Intravenous ferric carboxymaltose
Primary outcomes (2)
- measure
- Number of patients transfused allogenic red blood cells
- timeFrame
- Patients will be followed from recruitment to the study until postoperative discharge from hospital, which will be an expected average of 4 weeks
- description
- To determine if the administration of intravenous iron reduces the number of expected allogenic red blood cell transfusions from recruitment to the perioperative phase
- measure
- Hemoglobin levels
- timeFrame
- Patients will be followed from recruitment to the study until 8 weeks post operatively, which will be an expected average of 10 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Diagnosed with colonic or rectal adenocarcinoma * Defined date of operation at least 14 days from recruitment to study * Confirmed anemia * Females of child bearing age must agree to use a medically accepted form of contraceptive Exclusion Criteria: * Patient's who are unable to consent * Recognized allergy or intolerance of the study drug or excipients * Patients with previous or current hematological disease that in the investigators' opinion would confound the diagnosis of anemia
References
Publications (0)
Data not yet available